Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1999-6-3
pubmed:abstractText
We hypothesize that tumor angiogenesis can be limited by the reduction of enzymatic activity of the urokinase type plasminogen activator. The proposed mechanism is elimination of proteolytic activity by the advancing tip of capillaries which utilize proteolysis to produce space needed for vessel expansion. To test our hypothesis, we have investigated the angiostatic activity of synthetic low molecular weight inhibitors of urokinase: amiloride, benzamidine, EGCG, B428, and B623 using the chicken embryo corioallantoic membrane (CAM) model. We found that all tested inhibitors of urokinase cause a significant reduction of angiogenesis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1021-335X
pubmed:author
pubmed:issnType
Print
pubmed:volume
6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
523-6
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed:articleTitle
Angiostatic activity of synthetic inhibitors of urokinase type plasminogen activator.
pubmed:affiliation
Department of Physiology and Molecular Medicine, Medical College of Ohio, Toledo, OH 43614-2589, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't